A novel dual mechanism-of-action bispecific PD-1-IL-2v armed by a “βγ-only” interleukin-2 variant

A novel dual mechanism-of-action bispecific PD-1-IL-2v armed by a “βγ-only” interleukin-2 variant

IntroductionInterleukin-2 (IL-2) is one of the first cytokines to be discovered as an immune agonist for cancer immunotherapy. Biased IL-2 variants had been discovered to eliminate Treg activation or enhance the tumor specific T cell cytotoxicity. However, all the biased IL-2 variants pose the risk...

Full description

Bibliographic Details
Main Authors: Yongji Jiang, Chuyuan Chen, Yuan Liu, Rong Wang, Chuan Feng, Lili Cai, Shuang Chang, Lei Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Immunology
Subjects:
interleukin-2
cytokine
bispecific antibody
T cell activation
cancer immune therapy
IL-2 variant
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1369376/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1369376/full

Similar Items